DPCO Pharma Pricing & Cost Records

The Drug Prices Control Order 2013 (DPCO 2013) is issued by the Government of India under Section 3 of the Essential Commodities Act 1955 and vests price-fixing authority in the National Pharmaceutical Pricing Authority (NPPA). DPCO 2013 covers all formulations of medicines listed in Schedule I (the National List of Essential Medicines, NLEM) and fixes ceiling prices for these scheduled formulations based on a market-based pricing formula set out in paragraph 4 of the DPCO 2013. Non-scheduled formulations (those not in NLEM) are not subject to ceiling prices but are regulated under paragraph 20 of DPCO 2013, which restricts manufacturers from increasing the Maximum Retail Price (MRP) by more than 10% per annum. The NPPA regularly revises the NLEM list following Health Ministry notifications, and any medicine added to the NLEM automatically becomes a scheduled formulation subject to ceiling price control from the date of the notification.

The ceiling price for a scheduled formulation is calculated using the market-based pricing formula prescribed in paragraph 4 of the DPCO 2013: the ceiling price equals the simple arithmetic mean of all branded and generic versions of that formulation whose market share is at least 1% of the total market turnover of that formulation, based on data from the All India Organisation of Chemists and Druggists (AIOCD) or other NPPA-designated market data source. To this calculated price, a 16% trade margin is added to arrive at the MRP (Maximum Retail Price) as notified by the NPPA. Once notified, no manufacturer can sell a scheduled formulation above this ceiling MRP; any overcharging is a violation of DPCO 2013 enforceable under Section 3(2B) of the Essential Commodities Act 1955. Annual revision of ceiling prices is carried out by the NPPA to account for changes in the Wholesale Price Index for bulk drugs as per paragraph 16 of DPCO 2013.

Under paragraph 26 of DPCO 2013, every manufacturer of scheduled and non-scheduled formulations must submit monthly production and price data to the NPPA in the prescribed format (Form I, II, or III as applicable) by the 15th of the following month. Manufacturers must ensure that the MRP printed on the label of scheduled formulations does not exceed the ceiling price notified by the NPPA, and must report any revision in the price of non-scheduled formulations to the NPPA before effecting the increase under paragraph 20. Paragraph 30 of DPCO 2013 requires manufacturers to maintain records of production, sales, and pricing for a minimum of five years and to make them available for inspection by NPPA officers. Non-compliance with price-data reporting or selling above the ceiling price can result in recovery of overcharged amounts with interest under the Essential Commodities Act 1955, and repeated violations attract criminal prosecution under Section 7 of the Essential Commodities Act.

The NPPA revises ceiling prices of scheduled formulations annually based on the movement of the Wholesale Price Index (WPI) for bulk drugs as published by the Office of the Economic Adviser, Ministry of Commerce and Industry, under paragraph 16 of DPCO 2013. If the WPI increases, ceiling prices are proportionally revised upward; if the WPI declines, ceiling prices may be reduced, compressing manufacturer margins. Manufacturers are notified of revised ceiling prices through NPPA pricing orders and must implement the revised MRP on new stock produced after the notification date. Companies should build WPI-linked pricing models and factor in annual ceiling price revisions when setting transfer prices, distribution margins, and profitability targets. Strategies such as launching new dosage strengths, fixed-dose combinations (which may be outside the current NLEM), or patented formulations (where DPCO pricing does not apply in the same manner) can be explored within the constraints of the Drugs and Cosmetics Act 1940 and the DPCO 2013.

Under DPCO 2013, the ceiling price formula under paragraph 4 applies equally to all formulations — branded and unbranded — included in the NLEM, and no manufacturer is permitted to sell above the notified ceiling price regardless of branding. However, the marketing and trade margin structure differs: branded formulations typically carry higher trade margins driven by promotional practices, while the DPCO 2013 and subsequent NPPA orders (such as NPPA Order No. 2/2018 dated September 2018 on trade margin rationalisation) seek to cap trade margins on certain formulations at specific levels throughout the distribution chain. The National Medical Commission's promotion of unbranded generics and the government's push through the Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana create pricing pressure on branded generic businesses. Companies manufacturing both scheduled and non-scheduled formulations must maintain separate pricing registers for each category and ensure that cross-subsidisation of prices does not lead to violations of the ceiling price provisions of DPCO 2013.